Laboratoire GlaxoSmithKline SAS

-动脉网“供需对接”产业链接平台，高效对接行业资源，助力业绩增长 -截止目前，动脉网已上线链接近千条，每条链接的曝光量1W+，实现企业成功对接次数超2千次 -持续精选链接整理合集发布，并精准推送到动脉网相关领域社群（总覆盖人数超3W+） 北京阳光诺和药物研究股份有限公司是科创板上市企业（688621），是专注于仿制和创新药物研究，致力于以技术服务为核心，推动中国医药行业发展，为客户提供「临床前＋临床+CDMO」全过程药物研发服务的综合型CRO公司。阳光诺和从药物发现、到药理药效、药学研究，再到临床研究资源的整合，生物样本检测团队的构建，生产制造能力的整合，成功打造了全过程CRO服务模式。 公司主营业务涵盖药理药效、临床研究、CDMO、创新药开发、仿制药开发及一致性评价的综合研发服务，服务内容主要包括药物发现、药理药效、药学研究、临床研究和生物分析。可进行完整的化学药研发、仿制药一致性评价、药物代谢分析与评价研究、多肽药物研发、临床生物等效性试验、药物Ⅰ-Ⅳ期临床研究、生物样品检测、注册申报（国内和进口）、国际合作等服务。 本期链接专场为大家带来11个阳光诺和CRO服务项目，招募有研发需求的企业，详情如下： 雷美替胺片 1、基本信息 产品名称：雷美替胺片 英文名称：Ramelteon 商品名称：Rozerem 原研厂家：武田薬品工業株式会社（Takeda Pharmaceutical Co,.Ltd.） 产品规格：8mg 注册分类：3类 2、项目优势 雷美替胺，2005年9月获FDA批准在美国上市，商品名为Rozerem，可用于治疗难以入睡型失眠症，对慢性失眠和短期失眠也有确切疗效。本品能选择性激动褪黑激素1型受体和2型受体（MT1、MT2），增加慢波睡眠（SWS）和快动眼睡眠（REW），从而减少失眠。雷美替胺是首个没有列为特殊管制的非成瘾失眠症治疗药物。 雷美替胺吸收迅速，空腹口服给药后约0.75小时达峰。由于广泛的首过代谢，雷美替胺绝对口服生物利用度仅为1.8%。在人血清中，雷美替胺的体外蛋白结合率约为82%，与浓度无关。与白蛋白的结合占该结合的大部分，因为70%的药物与人血清白蛋白结合。代谢主要包括氧化成羟基和羰基衍生物，次生代谢产生葡糖苷酸结合物。CYP1A2 是参与雷美替胺肝脏代谢的主要同工酶；口服放射性标记的雷美替胺后，84%的总放射性通过尿液排出，约4%通过粪便排出，平均回收率为88%。少于0.1%的剂量作为母体化合物从尿液和粪便中排出。给药后96小时基本消除。由于雷美替胺的消除半衰期短（平均约1至2.6小时），每天重复服用一次不会导致显着蓄积。 3、临床适用于 用于治疗难以入睡型失眠症 4、上市情况 国内暂无上市企业 国外上市情况：2005年7月，ROZEREM片剂在美国被批准用于治疗“以入睡困难为特征的失眠症”。在日本，它因具有“改善失眠症入睡困难”的功效，于2010年4月作为不属于“精神药物”或“注意：成瘾”类别的药物批准生产和销售。2019年6月公布复审结果，再次确认有用性。 5、国内申报情况 国内有2家企业申请了临床，分别是南京正大天晴制药有限公司和越洋医药开发（广州）有限公司。 6、参比制剂的选择  国家局发布的仿制药参比制剂目录（第三十批），详见如下： 参考以上信息，雷美替胺片的处方工艺开发，可选择日本武田薬品工業株式会社上市的Rozerem作为参比制剂，规格为8mg，参比制剂生产商为武田薬品工業株式会社 くすり相談室，生产地址为〒103-8668 東京都中央区日本橋本町二丁目1番1号。 7、研发进度 阳光诺和拥有雷美替胺原料及制剂的成熟制备工艺，原料中试交接已完成，制剂即将进行中试。 非奈利酮片 1、基本信息 产品名称：非奈利酮片 英文名称：Finerenone Tablets 商品名称：Kerendia（可申达） 原研厂家：Bayer 产品规格：10mg和20mg 注册分类：4类 2、项目优势 非奈利酮片（通用名：Finelenone，以下简称Finelenone）是拜耳公司开发的一种新型非甾体类选择性盐皮质激素受体拮抗剂（MRA）。适用于与2型糖尿病相关的慢性肾脏病成人患者（肾小球滤过率估计值[eGFR]≥25至<75mL/min/1.73m2，伴白蛋白尿），可降低eGFR持续下降、终末期肾病的风险。 非奈利酮是一种非甾体类、选择性盐皮质激素受体（MR）拮抗剂，MR可被醛固酮和皮质醇激活并调节基因转录，MR过度激活会导致纤维化和炎症。非奈利酮是MR的强效和选择性拮抗剂，可阻断上皮（如肾脏）和非上皮（如心脏和血管）组织中MR介导的钠重吸收和MR过度激活，对雄激素、孕激素、雌激素和糖皮质激素受体无亲和力。 3、临床适用于 降低2型糖尿病相关的终末期肾病的风险 4、上市情况 国内目前仅参比上市，持证商拜尔，规格10mg、20mg。 5、国内申报情况 暂无企业申请上市。 6、市场情况 7、参比制剂的选择  NMPA发布的参比制剂目录信息： 综上所述，选择Bayer上市的原研药品，商品名：Kerendia（可申达），作为参比制剂。 8、专利情况 化合物专利CN101641352B，保护期至2028年2月19日CN106795155A，原研api合成路线，保护期至2035年 9、研发进度 非奈利酮片预BE已完成，项目经验成熟。 对乙酰氨基酚布洛芬片 1、基本信息 产品名称：对乙酰氨基酚布洛芬片 英文名称：Ibuprofen，Acetaminophen tablet 商品名称：Advil Dual Action With Acetaminophen 原研厂家：GlaxoSmithKline Consumer Healthcare 产品规格：对乙酰氨基酚250mg，布洛芬125mg 注册分类：3类 2、项目优势 对乙酰氨基酚是一种常用的苯胺类解热镇痛药，患者服用后不会产生过敏反应和积累中毒，临床上多用于治疗头痛、发烧及缓解轻度至中毒疼痛，也适用于治疗由普通感冒和病毒感染所引起的头痛、发烧及全身不适，还可作为有效的止痛药。维生素C具有增强机体对传染病的抵抗力，促进抗体形成，增加白细胞吞噬功能以及抗炎抗过敏作用，并能增加机体对病毒的抵抗力和对毒物的分解能力。 布洛芬是一种常用的解热镇痛消炎药，临床上主要用于解热及因为高热引起的关节疼痛、神经痛、痛经及其它疾病所引起的疼痛。布洛芬是由Stewart Adams博士和其导的团队、化学家John Nichokson博士共同发现的。其是在开发治疗类风湿关节炎的“超级阿司匹林”过程中长期研究的产物。将布洛芬誉为“超级阿司匹林”，意味着与当时的其他药物相比，疗效相同，但更具安全性。 3、临床适用于 解热镇痛消炎。 4、国内、外上市情况 目前国内有一家企业（广州南新）上市复方布洛芬片，每片含布洛芬400mg,对乙酰氨基酚325mg。 5、国内申报情况 目前国内有2家企业申报，山东朗诺和长春澜江，申报的规格均为对乙酰氨基酚250mg，布洛芬125mg。 6、市场销售情况 对乙酰氨基酚布洛芬片在国内还未上市，暂无销售数据。布洛芬片为OTC，以下为我公司数据库部分样本医院数据： 7、参比制剂的选择 NMPA发布的参比制剂目录信息 综上所述，按现行管理法规要求，选用GlaxoSmithKline Consumer Healthcare在美国上市的原研药品，商品名为Advil Dual Action With Acetaminophen，规格：对乙酰氨基酚250mg，布洛芬125mg，作为参比制剂。 8、专利情况 无专利限制。 9、研发进度 处方工艺开发中。 布洛芬盐酸去氧肾上腺素片 1、基本信息 产品名称：布洛芬盐酸去氧肾上腺素片 英文名称：Ibuprofen and Phenylephrine Hydrochloride Tablets 商品名称：Advil Congestion Relief 原研厂家：GlaxoSmithKline Consumer He 产品规格：布洛芬200mg，盐酸去氧肾上腺素10mg 注册分类：3类 2、项目优势 抗感冒药是一个庞大的家族，是最大类别的药品，依据抗感冒药所含血管收缩药的不同种类，可将抗感冒药分为三代：第一代苯丙醇胺类抗感冒药：2000年以前，国内外的抗感冒药以苯丙醇胺（去甲麻黄碱、PPA）类为主。第二代伪麻黄碱类抗感冒药：自2000年开始停用含苯丙醇胺的抗感冒药后，各国相继采用伪麻黄碱组成新的抗感冒药。第三代去氧肾上腺素类抗感冒药：美国的研究证实了口服去氧肾上腺素收缩血管、消除闭塞的作用，确定了其在抗感冒药中的地位。布洛肾素片的原研产品于2010年5月获得FDA批准上市销售，由美国Pfizer INC开发成功。目前该产品由GSK作为持证商在对外销售，是OTC产品。 3、上市情况 国内暂无上市企业 4、国内申报情况 国内仅阳光诺和申请临床试验 5、参比制剂的选择 国家局发布的仿制药参比制剂目录（第二十九批），详见如下： 参考以上信息，布洛芬盐酸去氧肾上腺素片的处方工艺开发，可选择美国GlaxoSmithKline Consumer Healthcare上市的Advil Congestion Relief作为参比制剂，规格为布洛芬200mg,盐酸去氧肾上腺素10mg。 6、研发进度 阳光诺和拥有布洛芬盐酸去氧肾上腺素片的成熟制备工艺，目前正在准备进行临床试验。 阿加曲班注射液 1、基本信息 产品名称：阿加曲班注射液 英文名称：Argatroban Injection 商品名称：NOVASTAN(诺保思泰) 原研厂家：田边三菱制药株式会社 产品规格：2mL:10mg 注册分类：4类 2、项目优势 阿加曲班是由日本三菱制药工场株式会社研制合成的抗血栓药，于1990年2月最先上市，首先被应用于临床治疗周围动脉闭塞性疾病，然后开始将其用于治疗急性脑血栓形成，以及心肌梗死溶栓的辅助治疗，并用于在抗凝血酶(AT)缺乏患者进行血透时的抗凝处理。美国食品与药品管理局（FDA）在2000年批准了史克必成和得克萨斯生物技术公司的可注射抗血栓小分子药物阿加曲班应用于治疗和预防血栓形成及肝素诱导的免疫性疾病－血小板减少症（HIT），以及用于对需要进行经皮冠脉介入术（PCI）病人的治疗。阿加曲班2001年在韩国上市。2002年12月，三菱制药公司正式在中国上市，规格：2ml：10mg，商品名：诺保思泰。 3、上市情况 目前国内26家上市，其中1家参比，23家过评。本品已经集采。部分上市情况如下： 4、国内申报情况 目前国内7家企业申请上市，湖南恒生、浙江华海、华夏生生等。 5、市场情况 6、参比制剂的选择 NMPA发布的参比制剂目录信息： 综上所述，选择田边三菱制药株式会社在国内上市的原研药品，商品名：NOVASTAN(诺保思泰)，作为参比制剂。 7、专利情况 无专利限制。 8、研发进度 阳光诺和拥有阿加曲班注射液的成熟制备工艺，现已拿到生产批件，可以对外转让。 度他雄胺软胶囊 1、基本信息 产品名称：度他雄胺软胶囊 英文名称：Dutasteride Soft Capsules 商品名称：Avodart(安福达) 原研厂家：GlaxoSmithKline (Ireland) Ltd. 产品规格：0.5mg 注册分类：4类 专利情况：无专利限制 2、项目优势 度他雄胺（Avodart，葛兰素史克）是第2代5α-还原酶抑制药，是目前第一种也是唯一一种同时抑制I型和II型5α-还原酶的药物，2001年由美国食品与药品管理局（FDA）批准在美国上市，用于治疗良性前列腺增生症。长时间服用能减小前列腺体积，因此目前被FDA批准用于降低急性尿潴留和相关手术风险。在欧洲市场的商品名为Avolvet。 国家食品药品监督管理局于2011年4月11日批准了法国Laboratoire GlaxoSmithKline公司的度他雄胺软胶囊（商品名为安福达/Avodart、规格为0.5mg）进口上市申请，进口注册证号为H20110205。 3、临床适用于 治疗良性前列腺增生症。 4、上市情况 目前国内6家企业上市，1家参比、5家过评。本品已集采。 5、国内申报情况 目前无最新申报企业。 6、参比制剂的选择 NMPA发布的参比制剂目录信息： 综上所述，选择GlaxoSmithKline (Ireland) Ltd.在国内上市的原研药品，商品名：Avodart(安福达)，作为参比制剂。 7、研发进度 阳光诺和拥有度他雄胺软胶囊的成熟制备工艺，现已拿到生产批件，可以对外转让。 盐酸多西环素片 1、基本信息 产品名称：盐酸多西环素片 英文名称：Doxycycline Hyclate Tablets 商品名称：Vibramycin 原研厂家：Pfizer Japan Inc 产品规格：0.1g 注册分类：3类 2、项目优势 多西环素是一种四环素类抗生素，通常用于治疗各种感染。它是一种广谱抗生素和抑菌剂。强力霉素具有抗原生动物特性，是体内MMPs（基质金属蛋白酶）的有效抑制剂。强力霉素经常用于治疗莱姆病，慢性前列腺炎，鼻窦炎，盆腔炎痤疮，酒渣鼻和立克次体感染和预防治疗炭疽（由炭疽芽孢杆菌引起）。对鼠疫菌也有效。治疗与强力霉素抑制胶原合成。 3、临床适用于 浅表性皮肤感染、深表性皮肤感染、淋巴管淋巴结炎、慢性脓皮病、外伤烧伤及手术创等二次感染、乳腺炎、骨髓炎、喉咽喉炎、扁桃体炎、急性支气管炎、肺炎等引起的感染。 4、上市情况 目前国内有61家上市，仅江苏联环1家通过一致性。部分上市情况如下： 5、国内申报情况 目前国内2家申报，特一药业申请一致性，浙江赛默申请上市。 6、市场情况 7、参比制剂的选择 NMPA发布的参比制剂目录信息： 综上所述，选择Pfizer Japan Inc在日本上市的原研药品，商品名：Vibramycin，作为参比制剂。 8、专利情况 无专利限制。 9、研发进度 阿达帕林过氧苯甲酰凝胶正在进行中试生产，项目经验成熟。 苹果酸奈诺沙星胶囊 1、基本信息 产品名称：苹果酸奈诺沙星胶囊 英文名称：Nemonoxacin Malate Capsules 商品名称：太捷信 原研厂家：浙江医药股份有限公司新昌制药厂 产品规格：0.25g 注册分类：4类 2、项目优势 奈诺沙星（nemonoxacin，TG-873870）具有广谱的抗革兰阳性菌、革兰阴性菌和非典型病原体的体外抗菌活性，包括耐青霉素、耐喹诺酮类的肺炎链球菌并且对耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)、耐万古霉素金黄色葡萄球菌和多重耐药病原菌有效。奈诺沙星C-8位点比沿用的喹诺酮类多一个甲基基团，使得与拓扑异构酶Ⅳ和Ⅱ均能结合，从而抗菌谱更广，诱导耐药减少。 奈诺沙星是由台湾太景（TaiGen）生物科技公司从宝洁(P&G)制药获得许可研发的一种新型C-6位无氟喹诺酮类药物，并由该公司授权予浙江医药股份有限公司在中国大陆生产与销售。现应用者为苹果酸奈诺沙星（nemonoxacin malate），与沿用的喹诺酮类抗菌药物相比，奈诺沙星对革兰阳性球菌具有更高的抗菌活性。 3、临床适用于 抗细菌感染 4、上市情况 目前国内苹果酸奈诺沙星胶囊仅1家企业上市，浙江医药股份有限公司新昌制药厂（原研），规格：0.25g(以C20H25N3O4计)。上市情况如下： 5、国内申报情况 暂无企业申报仿制上市。 23年1月，浙江医药股份有限公司新昌制药厂（原研）申请临床。 23年6月，治疗单纯性尿路感染III期临床进行中。 6、市场情况 苹果酸奈诺沙星胶囊的销售数据如下： 7、参比制剂的选择 NMPA发布的参比制剂目录信息： 综上所述，可以选择原研药品（持证商：浙江医药股份有限公司新昌制药厂；商品名：太捷信）在国内上市的苹果酸奈诺沙星胶囊，作为参比制剂。 8、专利情况 9、研发进度 阳光诺和目前正在进行实验室处方工艺研究。 阿达帕林过氧苯甲酰凝胶 1、基本信息 产品名称：阿达帕林过氧苯甲酰凝胶 英文名称：Adapalene and Benzoyl Peroxide Gel 商品名称：Epiduo 原研厂家：Laboratoires Galderma S.A. 产品规格：0.1%,2.5%（15g） 注册分类：3→4类 2、项目优势 阿达帕林属第三代维A酸，是一种萘甲酸衍生物，它与维A酸核受体有特殊的亲和力，与第一代的维A酸和异维A酸不同，它不与胞腺维A酸蛋白相结合，比原有的维A酸制剂对皮肤的刺激更低。而且其稳定性好，避免了维A酸仅限于晚上使用（维A酸光不稳定，需避光）。过氧化苯甲酰为苯甲酸衍化物，具有广谱抗菌作用，尤其抗厌氧菌性感染，对痤疮丙酸杆菌（痤疮丙酸杆菌）和表皮葡萄球菌（表皮葡萄球菌）具有抗菌活性，且有去角质作用。其最大特点是不会耐药。根据CN101541320B原研专利研究结果可知，BPO可增强阿达帕林的作用，在保持同样的皮肤耐受性的同时，联合应用或组合使用阿达帕林和BPO的治疗方法可以成功地减少痤疮的皮损数量并改善病人的临床症状，疗效显著优于以单独应用阿达帕林或单独应用BPO为基础的治疗方法。 3、临床适用于 寻常性痤疮的局部治疗 4、上市情况 国内暂无阿达帕林过氧苯甲酰凝胶上市。有阿达帕林凝胶单方和过氧苯甲酰凝胶单方上市，上市情况如下： 5、国内申报情况  目前国内有2家申请上市：原研Galderma、苏州高迈。 23年1月，原研Galderma申请上市，预计24年底或25年初获批。 6、市场情况 由于国内阿达帕林过氧苯甲酰凝胶还未上市，所以暂无复方的销售数据。 阿达帕林凝胶单方和过氧苯甲酰凝胶单方的销售数据如下： 7、参比制剂的选择 NMPA发布的参比制剂目录信息： 综上所述，选择Laboratoires Galderma S.A.上市的原研药品，商品名：Epiduo。 8、专利情况 无专利限制。 9、研发进度 阿达帕林过氧苯甲酰凝胶正在进行中试生产，项目经验成熟。 多替诺雷片 1、基本信息 产品名称：多替诺雷/多替诺德片 英文名称：Dotinurad Tablets 商品名称：URECE 原研厂家：Fuji Yakuhin Co., Ltd. 产品规格：0.5mg、1mg、2mg 注册分类：3类 2、项目优势 多替诺雷片（通用名：ドチヌラド）是一种具有选择性URAT1抑制作用的药物，并且致力于减少肝脏毒性（如线粒体毒性）和CYP2C9抑制引起的药物相互作用，由富士药品公司研发，是一种选择性尿酸再吸收抑制药（Selective Urate Reabsorption Inhibitor：SURI）。 多替诺雷片的开发从2009年开始，针对痛风和高尿酸血症患者的临床试验由富士药品公司进行，第Ⅲ期试验则由富士药品公司与持田制药公司共同进行。由于确认了多替诺雷片的有效性和安全性，最终申请了“痛风、高尿酸血症”作为适应症，并于2020年1月23日获得了生产销售许可，商品名为URECE，规格为0.5mg、1mg和2mg。高尿酸血症如果持续存在，会引发痛风关节炎（痛风），并导致生活质量下降。此外，高尿酸血症不仅与痛风相关，还可能与肾脏损伤和心血管事件的发生有关。因此，降低痛风和高尿酸血症患者的血清尿酸值是非常重要的。在治疗痛风和高尿酸血症时，生活习惯的调整是基本原则，药物治疗也同样重要。 3、临床适用于 痛风、高尿酸血症 4、上市情况 目前国内暂无上市企业 5、国内申报情况 原研中国临床3期完成，即将上市（临床做的规格是1和2mg）。 6、市场情况 国内暂无上市，所以暂无销售数据。 7、参比制剂的选择  NMPA发布的参比制剂目录信息： 综上所述，选择Fuji Yakuhin Co., Ltd.在日本上市的原研药品，商品名：URECE，作为参比制剂。 8、专利情况 9、研发进度 多替诺雷原料准备中试，制剂正在做实验室研究。 注射用盐酸兰地洛尔 1、项目优势 注射用盐酸兰地洛尔是由日本小野制药开发的一款用于治疗快速性心律失常的注射药物制剂，是一种新型的超短效肾上腺素β受体阻滞药。肾上腺素β受体阻滞药是一类作用广泛、重要的心血管治疗药物，超短效肾上腺素β受体阻滞药由于起效快、代谢快、停药后β受体阻滞作用消失快，发生的快速性心律失常的治疗中发挥重要且不可替代的作用。 2、临床适用于 1）手术过程中发生的下列快速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速； 2）手术后循环系统动态监护时发生的快速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速； 3）心功能不全患者发生下列快速性心律失常的治疗：心房纤颤、心房扑动； 国内无原研产品上市，仅一家仿制药上市 3、项目进度 阳光诺和兰地洛尔原料药工艺验证完成，制剂即将工艺验证。 对以上项目感兴趣，欢迎扫描下方二维码，与阳光诺和直接对接 -动脉网供需对接平台覆盖：出海、供应链、市场/渠道、成果转化、招商入驻等板块 -通过平台上传供应或需求资源内容，可精准触达目标意向合作伙伴 -高效对接MNC、初创企业、政府园区、投资机构等实体 下载动脉网APP，自主发布，高效对接 近 期 推 荐 声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。 动脉网，未来医疗服务平台

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Emergency contraceptive pills market insights - Continue Reading Technavio has announced its latest market research report titled Global Emergency Contraceptive Pills Market 2023-2027 Vendors: 15+, Including AbbVie Inc. | Afaxys Pharma LLC | Bayer AG | Combe Inc. | Foundation Consumer Healthcare LLC | Gedeon Richter Plc | HLL Lifecare Ltd. | Knoll Healthcare Pvt. Ltd. | Laboratoire HRA Pharma SAS | Lupin Ltd. | Mankind Pharma Ltd. | Morepen Laboratories Ltd. | Perrigo Co. Plc | Pfizer Inc. | Piramal Enterprises Ltd. | Sun Pharmaceutical Industries Ltd. | Syzygy Healthcare LLC | Teva Pharmaceutical Industries Ltd., among others Coverage: Key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: Distribution Channel (Retail stores and Online stores), Type (Combination pills and Progesterone pills), and Geography (North America, Europe, Asia, and Rest of World (ROW)) To understand more about the emergency contraceptive pills market, request a sample report The emergency contraceptive pills market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects. Why Buy? Add credibility to the strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio- Buy the Report In 2017, the emergency contraceptive pills market was valued at USD 831.35 million. From a regional perspective, North America held the largest market share, valued at USD 281.00 million. The emergency contraceptive pills market size is estimated to grow by USD 258.7 million from 2022 to 2027 at a CAGR of 4.83% according to Technavio. Emergency contraceptive pills market insights - Customer Landscape To help companies evaluate and develop growth strategies, the report outlines – Key purchase criteria Adoption rates Adoption lifecycle Drivers of price sensitivity For highlights on customer landscape analysis, download a sample ! Global emergency contraceptive pills market - Vendor Insights The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including - AbbVie Inc. - The company offers an emergency contraceptive pill, namely Liletta. Afaxys Pharma LLC - The company offers emergency contraceptive pills namely Annovera. Bayer AG: The company offers emergency contraceptive pills namely Yasmin. Combe Inc.: The company offers emergency contraceptive pills namely Preventeza. Global emergency contraceptive pills market – Market Dynamics Major drivers - Rise in the number of initiatives to create awareness Increase in unplanned pregnancies Ease of online purchase Key challenges - Local governments limiting access to emergency contraceptive pills Consumption and side effects Availability of alternative methods of contraception Drivers and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report! What are the key data covered in this emergency contraceptive pills market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the Emergency Contraceptive Pills Market between 2023 and 2027 Precise estimation of the size of the Emergency Contraceptive Pills Market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the Emergency Contraceptive Pills Market industry across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of Emergency Contraceptive Pills Market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: The female contraceptive market is estimated to grow at a CAGR of 5.32% between 2022 and 2027. The size of the market is forecasted to increase by USD 5,142.22 million. This report extensively covers market segmentation by distribution channel (offline and online), product (female contraceptive devices and female contraceptive drugs), and geography (North America, Europe, APAC, South America, and the Middle East and Africa). The emergency food market size is expected to decline by USD 2.88 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.23%. This report extensively covers segmentation by product type (ready-to-eat meals, non-perishable pasteurized milk, infant food, dried food, and others), distribution channel (offline and online), and geography (North America, Europe, APAC, South America, and Middle East and Africa). Table of contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 06: Executive Summary – Chart on Market Segmentation by Type Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global emergency contraceptive pills market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global emergency contraceptive pills market 2017 - 2021 ($ million) 4.2 Distribution channel Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million) 4.3 Type Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Distribution Channel 6.1 Market segments Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) 6.2 Comparison by Distribution Channel Exhibit 32: Chart on Comparison by Distribution Channel Exhibit 33: Data Table on Comparison by Distribution Channel 6.3 Retail stores - Market size and forecast 2022-2027 Exhibit 34: Chart on Retail stores - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Retail stores - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Retail stores - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Retail stores - Year-over-year growth 2022-2027 (%) 6.4 Online stores - Market size and forecast 2022-2027 Exhibit 38: Chart on Online stores - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Online stores - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Online stores - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Online stores - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Distribution Channel Exhibit 42: Market opportunity by Distribution Channel ($ million) 7 Market Segmentation by Type 7.1 Market segments Exhibit 43: Chart on Type - Market share 2022-2027 (%) Exhibit 44: Data Table on Type - Market share 2022-2027 (%) 7.2 Comparison by Type Exhibit 45: Chart on Comparison by Type Exhibit 46: Data Table on Comparison by Type 7.3 Combination pills - Market size and forecast 2022-2027 Exhibit 47: Chart on Combination pills - Market size and forecast 2022-2027 ($ million) Exhibit 48: Data Table on Combination pills - Market size and forecast 2022-2027 ($ million) Exhibit 49: Chart on Combination pills - Year-over-year growth 2022-2027 (%) Exhibit 50: Data Table on Combination pills - Year-over-year growth 2022-2027 (%) 7.4 Progesterone pills - Market size and forecast 2022-2027 Exhibit 51: Chart on Progesterone pills - Market size and forecast 2022-2027 ($ million) Exhibit 52: Data Table on Progesterone pills - Market size and forecast 2022-2027 ($ million) Exhibit 53: Chart on Progesterone pills - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Progesterone pills - Year-over-year growth 2022-2027 (%) 7.5 Market opportunity by Type Exhibit 55: Market opportunity by Type ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 57: Chart on Market share by geography 2022-2027 (%) Exhibit 58: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 59: Chart on Geographic comparison Exhibit 60: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 81: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 Germany - Market size and forecast 2022-2027 Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.10 France - Market size and forecast 2022-2027 Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 93: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 97: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 98: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 99: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 100: Overview on factors of disruption 11.4 Industry risks Exhibit 101: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 102: Vendors covered 12.2 Market positioning of vendors Exhibit 103: Matrix on vendor position and classification 12.3 AbbVie Inc. Exhibit 104: AbbVie Inc. - Overview Exhibit 105: AbbVie Inc. - Product / Service Exhibit 106: AbbVie Inc. - Key news Exhibit 107: AbbVie Inc. - Key offerings 12.4 Afaxys Pharma LLC Exhibit 108: Afaxys Pharma LLC - Overview Exhibit 109: Afaxys Pharma LLC - Product / Service Exhibit 110: Afaxys Pharma LLC - Key offerings 12.5 Bayer AG Exhibit 111: Bayer AG - Overview Exhibit 112: Bayer AG - Business segments Exhibit 113: Bayer AG - Key news Exhibit 114: Bayer AG - Key offerings Exhibit 115: Bayer AG - Segment focus 12.6 Combe Inc. Exhibit 116: Combe Inc. - Overview Exhibit 117: Combe Inc. - Product / Service Exhibit 118: Combe Inc. - Key offerings 12.7 Foundation Consumer Healthcare LLC Exhibit 119: Foundation Consumer Healthcare LLC - Overview Exhibit 120: Foundation Consumer Healthcare LLC - Product / Service Exhibit 121: Foundation Consumer Healthcare LLC - Key offerings 12.8 Gedeon Richter Plc Exhibit 122: Gedeon Richter Plc - Overview Exhibit 123: Gedeon Richter Plc - Business segments Exhibit 124: Gedeon Richter Plc - Key news Exhibit 125: Gedeon Richter Plc - Key offerings Exhibit 126: Gedeon Richter Plc - Segment focus 12.9 HLL Lifecare Ltd. Exhibit 127: HLL Lifecare Ltd. - Overview Exhibit 128: HLL Lifecare Ltd. - Product / Service Exhibit 129: HLL Lifecare Ltd. - Key offerings 12.10 Laboratoire HRA Pharma SAS Exhibit 130: Laboratoire HRA Pharma SAS - Overview Exhibit 131: Laboratoire HRA Pharma SAS - Product / Service Exhibit 132: Laboratoire HRA Pharma SAS - Key offerings 12.11 Lupin Ltd. Exhibit 133: Lupin Ltd. - Overview Exhibit 134: Lupin Ltd. - Product / Service Exhibit 135: Lupin Ltd. - Key news Exhibit 136: Lupin Ltd. - Key offerings 12.12 Mankind Pharma Ltd. Exhibit 137: Mankind Pharma Ltd. - Overview Exhibit 138: Mankind Pharma Ltd. - Product / Service Exhibit 139: Mankind Pharma Ltd. - Key offerings 12.13 Perrigo Co. Plc Exhibit 140: Perrigo Co. Plc - Overview Exhibit 141: Perrigo Co. Plc - Business segments Exhibit 142: Perrigo Co. Plc - Key news Exhibit 143: Perrigo Co. Plc - Key offerings Exhibit 144: Perrigo Co. Plc - Segment focus 12.14 Pfizer Inc. Exhibit 145: Pfizer Inc. - Overview Exhibit 146: Pfizer Inc. - Product / Service Exhibit 147: Pfizer Inc. - Key news Exhibit 148: Pfizer Inc. - Key offerings 12.15 Piramal Enterprises Ltd. Exhibit 149: Piramal Enterprises Ltd. - Overview Exhibit 150: Piramal Enterprises Ltd. - Business segments Exhibit 151: Piramal Enterprises Ltd. - Key offerings Exhibit 152: Piramal Enterprises Ltd. - Segment focus 12.16 Sun Pharmaceutical Industries Ltd. Exhibit 153: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 154: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 155: Sun Pharmaceutical Industries Ltd. - Key offerings 12.17 Syzygy Healthcare LLC Exhibit 156: Syzygy Healthcare LLC - Overview Exhibit 157: Syzygy Healthcare LLC - Product / Service Exhibit 158: Syzygy Healthcare LLC - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 159: Inclusions checklist Exhibit 160: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 161: Currency conversion rates for US$ 13.4 Research methodology Exhibit 162: Research methodology Exhibit 163: Validation techniques employed for market sizing Exhibit 164: Information sources 13.5 List of abbreviations Exhibit 165: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio